Skip to main content
Signal8

Trevena, Inc. (TRVN)

Trevena, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing innovative pharmaceutical solutions for individuals suffering from central nervous system disorders. Its pipeline features several promising drug candidates: OLINVYK (Oliceridine) injection: A G protein-biased mu-opioid receptor (MOR) ligand engineered to manage acute pain ranging from moderate to severe. TRV027: Aimed at addressing acute lung injury, which contributes to acute respiratory distress syndrome (ARDS) and abnormal blood clotting in patients with COVID-19. TRV250: A G protein-biased delta-opioid receptor agonist under development for the treatment of acute migraine. TRV734: A small molecule G protein-biased MOR ligand designed for the management of both moderate-to-severe acute and chronic pain. TRV045: An innovative S1P modulator focused on providing relief for chronic pain. The company has also established a partnership with Imperial College London to investigate TRV027's potential in patients afflicted with COVID-19. Trevena, Inc., founded in 2007, operates from its headquarters in Chesterbrook, Pennsylvania.

Sector: Biotechnology

Industry: Biotechnology

Trevena, Inc. logo

Trevena, Inc.

OTC:TRVNHealthcare
$0.0005
CLOSED
Mkt Cap$432
EV-
Float810K
O/S864K
VOL977 sh
$ Vol$0
RVOL2.18×
Inst Own0.0%
SI0.4%
Net Cash/Sh-
Dilution
Trevena, Inc. logoOTC:TRVNClosed$0.0005
Short interest (FINRA)
0.4%
Oct 30 (18d)

Float 810.18K · Signal8 estimate from ownership filings · Sep 17, 2024

3.3K
Oct 30 (18d)prev 3.2K▲ 1.5%
37.92
Oct 30 (18d)prev 13.84▲ 174.0%
Borrow (IBKR)

The cost to borrow TRVN shares for a short sale and how many IBKR has available, from IBKR's lendable-stock file, refreshed through the session.

IBKR borrow fee and availability is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually
Off-exchange & settlement
No fails on record for 16–31 Oct 2026.
Price, short interest & fails to deliver
Short interest · today's share basis23 settlements
Latest short interest settlements (today's share basis)
DateShares short
Oct 30, 20263.3K sh
Oct 15, 20263.2K sh
Sep 30, 20263.3K sh
Sep 15, 20263.3K sh
Aug 31, 20263.3K sh

A stock split executed inside this window; every settlement plotted has been carried onto today’s share basis, so the line does not step at the split.

The three panels share one date axis, so a point's position is its date; each has its own value axis. Short interest is plotted on today's share basis, so the line does not step where a split does.

Off-exchange short volume

FINRA publishes no off-exchange short volume for this symbol.

ATS venues (dark pools)

FINRA's weekly alternative trading system (dark pool) volume for TRVN: the share of off-exchange volume that traded on an ATS, and each venue by shares and trades.

The ATS venue breakdown is included in Signal8 ProUpgrade to Pro · $40.67/mo billed annually

As of the Oct 30, 2026 FINRA settlement, 3,261 TRVN shares were sold short (0.40% of a 810K-share float, 37.92 days to cover).